You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Longitudinal Neuroimaging Biomarkers in Huntington's Disease

Article type: Review Article

Authors: Rees, Elin M. | Scahill, Rachael I. | Hobbs, Nicola Z.

Affiliations: UCL Institute of Neurology, University College London, Queen Square, London, UK

Note: [] Correspondence to: Elin Rees, UCL Institute of Neurology, University College London, c/o Box 104, Queen Square, London, WC1N 3BG, UK. Tel.: +44 0207 242 0038; Fax: +44 0207 611 0129; E-mail: [email protected]

Keywords: Huntington's disease, longitudinal studies, biomarkers, magnetic resonance imaging, diffusion mri, functional mri, positron emission tomography

DOI: 10.3233/JHD-120030

Journal: Journal of Huntington's Disease, vol. 2, no. 1, pp. 21-39, 2013

Published: 2013
Get PDF open access

Abstract

Identifying markers able to characterise the progression of Huntington's Disease (HD) is of great importance to the HD research community, as such markers may provide valuable outcome measures in future clinical trials. Neuroimaging measures are obvious candidates because of their clear relevance to the neuropathology of the disease. Many also show improved precision and sensitivity compared with standard functional scales. This review summarizes findings from the wealth of longitudinal imaging studies in the literature, focusing on the most widely available imaging modalities: structural MRI (volumetric and diffusion imaging), functional MRI and PET. We discuss the longitudinal sensitivity, reproducibility and feasibility of each imaging modality for use in clinical trials.

Show more